EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF‐α inhibitors

Rodolfo David Palacios-Diaz, Antonio Sahuquillo-Torralba, Vicenç Rocamora-Durán, Blanca de Unamuno-Bustos, Miguel Salavert-Lleti, Sergio Santos-Alarcón, Adriana Quintero, Joan Garcías-Ladaria, Aina Vila-Payeras, Alvaro Martínez-Doménech, Almudena Mateu-Puchades, Cristina Nadal-Lladó und 1 weitere

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023

DOI: 10.1111/ddg.15007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Rodolfo David Palacios-Diaz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Leishmaniasis, Mucocutaneous, Leishmaniasis, Cutaneous, Antiprotozoal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives The increasing use of biologics in the treatment of inflammatory diseases has led to more cases of leishmaniasis in patients subjected to iatrogenic immunosuppression. The main objective was to describe the characteristics of the patients with cutaneous (CL) or mucocutaneous (MCL) leishmaniasis who were receiving a biological therapy at the time of diagnosis. Patients and methods A multicenter retrospective study was design based on a cohort of patients diagnosed with CL or MCL. All patients who were being treated with biologicals were included. For each case, two matched non‐exposed patients were included for comparison.

Results

38 patients were diagnosed with CL or MCL while being treated with tumor necrosis factor alpha (TNF‐α) inhibitors. Leishmaniasis presented more frequently as a plaque (58.3%) with a larger median lesion size (2.5 cm), ulceration (92.1%), and required a greater median number of intralesional meglumine antimoniate infiltrations (3 doses) ( P < 0.05) than in non‐exposed patients. We found no systemic involvement in patients being treated with anti‐TNF‐α. We did not find differences regarding the treatment characteristics whether biologic therapy was modified or not.

Conclusions

Although management should be individualized, maintenance of biologic therapy does not seem to interfere with treatment of CL or MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, MucocutaneousLeishmaniasis, CutaneousAntiprotozoal AgentsHumansRetrospective StudiesTumor Necrosis Factor InhibitorsMeglumine AntimoniateImmunologic Factors

Stichwörter der Autor:innen

PsoriasisTNF-αbiologic drugscutaneous leishmaniasisinflammatory diseasessystemic involvement

Substanzen

Tumor Necrosis Factor InhibitorsMeglumine AntimoniateImmunologic FactorsAntiprotozoal Agents

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Dermatology Department, Hospital de Manacor, Illes Baleares, Spain.
  • Infectious Diseases Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Dermatology Department, Hospital Universitario Doctor Peset, Valencia, Spain.
  • Pathology Department, Hospital de Manacor, Illes Baleares, Spain.
  • Dermatology Department, Hospital Universitario Son Espases, Illes Baleares, Spain.

Zitieren

APA

Palacios-Diaz, R. D., Sahuquillo-Torralba, A., Rocamora-Durán, V., Unamuno-Bustos, B., Salavert-Lleti, M., Santos-Alarcón, S., Quintero, A., Garcías-Ladaria, J., Vila-Payeras, A., Martínez-Doménech, A., Mateu-Puchades, A., Nadal-Lladó, C., & Botella-Estrada, R. (2023). Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF‐α inhibitors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15007

Vancouver

Palacios-Diaz RD, Sahuquillo-Torralba A, Rocamora-Durán V, Unamuno-Bustos B, Salavert-Lleti M, Santos-Alarcón S, et al. Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF‐α inhibitors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.15007

BibTeX
@article{PalaciosDiaz2023,
  author = {Palacios-Diaz, Rodolfo David and Sahuquillo-Torralba, Antonio and Rocamora-Durán, Vicenç and Unamuno-Bustos, Blanca de and Salavert-Lleti, Miguel and Santos-Alarcón, Sergio and Quintero, Adriana and Garcías-Ladaria, Joan and Vila-Payeras, Aina and Martínez-Doménech, Alvaro and Mateu-Puchades, Almudena and Nadal-Lladó, Cristina and Botella-Estrada, Rafael},
  title = {Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF‐α inhibitors},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2023},
  doi = {10.1111/ddg.15007}
}
Kostenlos starten →